Ascofuranone: a possible therapeutic tool for autosomal dominant polycystic kidney disease?

Mol Cancer Ther. 2010 Nov;9(11):3100; author reply 3101. doi: 10.1158/1535-7163.MCT-10-0741. Epub 2010 Oct 26.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cell Cycle / drug effects
  • Cell Cycle / genetics
  • Cell Proliferation / drug effects
  • Cyclin-Dependent Kinase Inhibitor p21 / genetics
  • Cyclin-Dependent Kinase Inhibitor p21 / metabolism
  • Cytostatic Agents / pharmacology
  • Cytostatic Agents / therapeutic use
  • Gene Expression Regulation / drug effects
  • Humans
  • Mutation / physiology
  • Polycystic Kidney, Autosomal Dominant / drug therapy*
  • Sesquiterpenes / pharmacology*
  • Sesquiterpenes / therapeutic use
  • TRPP Cation Channels / genetics

Substances

  • Cyclin-Dependent Kinase Inhibitor p21
  • Cytostatic Agents
  • Sesquiterpenes
  • TRPP Cation Channels
  • polycystic kidney disease 1 protein
  • ascofuranone